Analyst Gil Blum works at NEEDHAM and is focused on the Healthcare sector with 93 price targets and ratings documented since 2018 spanning on 17 stocks. Analyst's average stock valuation to be materialised ratio is 13.46% with an average time for price targets to be met of 37.85 days.
Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals, Inc at 04-Nov-2022.
Gil Blum best performing recommendations are on AGLE.
The best stock recommendation documented was for AGLE at 5/7/2020. The price target of $11 was fulfilled within 46 days with a profit of $3.13 (39.77%) receiving and performance score of 8.65.
Average potential price target upside